Goh Chung Meng

Mr Goh Chung Meng began his career in 1982 with the management consulting arm of deloitte & touche in singapore. During the period from 1985 to 1990, mr goh worked as a senior consultant for deloitte & touche management consultants where he was involved in a wide variety of consulting assignments for mnc clients including a two-year stint helping to start an insolvency unit during the 1985 recession. In 1990, he joined carr indosuez asia (merchant banking unit of credit agricole and formerly known as banque indosuez) and in 1995, he joined a us$200 million asian venture capital fund known as suez asia holdings, where he was director, investments, of the fund focusing on southeast asia and china private equity investments. Mr goh is currently a director (alternate) of taurx pharmaceuticals ltd (taurx), a drug discovery company which has completed and published the results of two global phase 3 human clinical trials in alzheimer’s disease in the lancet and the journal of alzheimer’s disease (jad) with a third clinical trial pending top line results in 2022. Mr. Goh has been a pioneer board member of the taurx group since its founding as a startup in 2002. Mr goh was formerly a qualified business angel of the national science and technology board in 2001 and he had served as a panel member (2001 to 2008) of a singapore government innovation and research fund, the enterprise challenge unit (tec), ps21 office, public service division, prime minister’s office.